Seelos Therapeutics, Inc. announced that Tim Whitaker will now serve as Chief Medical Officer (CMO) for the company, formerly serving as Head of Research and Development, and Warren W. Wasiewski will now serve as Senior Neuro Advisor. Kimberly Farrand joined the company in July 2020 as the company’s Senior Director, Clinical Development and Operations. Farrand possesses over 20 years of experience in the industry and spent over 17 years at Shire Pharmaceuticals prior to its acquisition by Takeda Pharmaceutical Company. Lucas Pilipski joined the company in December 2020 as the company’s Executive Director of Clinical Operations. Pilipski has over 17 years of industry experience and spent over four years at Sanofi S.A. and eight years at Shire Pharmaceuticals. Manira Rayamajhi joined the company in July 2020 as the company’s Associate Director, Global Regulatory Affairs. She has 10 years of experience spanning multiple therapeutic areas and in all phases of development. She was a Postdoctoral Research Fellow at the University of North Carolina at Chapel Hill for 5 years and previously worked at Carmago Pharmaceutical Services, Syneos Health, and MMS Holdings in various capacities. David M. Biondi, DO, FAAN has also joined the company as a consultant with an extensive background in medical practices and the pharmaceutical industry. Biondi served as a neurologist in the United States Navy and later in community and academic practice settings. He held medical affairs and clinical development roles at Janssen Pharmaceuticals, Johnson & Johnson, and Alder Biopharmaceuticals. He most recently served as Executive Director for Clinical Programs at Cohen Veterans Bioscience and currently sits on their Board of Directors.